18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Metastatic Prostate Cancer
Recruiting
18-99 years
Male
Phase
1
30 participants needed
1 Location
Brief description of study
The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to take computerized pictures of places in the body where prostate cancer has spread (metastasized). The pictures will be taken before, and optionally after treatment. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Metastatic Prostate Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: Male
Males. over age 18, diagnoses with Metastatic Prostate Cancer
Updated on
01 Aug 2024.
Study ID: 849671
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
